CorMedix to Participate in Upcoming Investor Conferences
CorMedix (NASDAQ:CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening conditions, announced its participation in two major healthcare investor conferences in September 2025.
The company's senior management will present at the Cantor Global Healthcare Conference on September 5 at 8:35am ET and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10 at 10:45am ET. Both presentations will be in a fireside chat format with webcasts available.
CorMedix (NASDAQ:CRMD), una società biofarmaceutica specializzata in prodotti terapeutici per condizioni potenzialmente letali, ha annunciato la sua partecipazione a due importanti conferenze per investitori nel settore sanitario a settembre 2025.
Il management senior presenterà al Cantor Global Healthcare Conference il 5 settembre alle 8:35 ET e al Morgan Stanley 23rd Annual Global Healthcare Conference il 10 settembre alle 10:45 ET. Entrambe le presentazioni saranno in formato "fireside chat" e trasmesse in webcast.
CorMedix (NASDAQ:CRMD), una compañía biofarmacéutica especializada en productos terapéuticos para afecciones potencialmente mortales, anunció su participación en dos importantes conferencias para inversores del sector sanitario en septiembre de 2025.
La alta dirección presentará en el Cantor Global Healthcare Conference el 5 de septiembre a las 8:35 ET y en el Morgan Stanley 23rd Annual Global Healthcare Conference el 10 de septiembre a las 10:45 ET. Ambas presentaciones serán en formato de charla informal (fireside chat) y estarán disponibles por webcast.
CorMedix (NASDAQ:CRMD), 생명을 위협하는 질환을 위한 치료 제품을 전문으로 하는 바이오제약 회사가 2025년 9월 두 개의 주요 의료 투자자 콘퍼런스에 참가한다고 발표했습니다.
회사 고위 경영진은 Cantor Global Healthcare Conference에 9월 5일 오전 8:35(ET)에, Morgan Stanley 23rd Annual Global Healthcare Conference에 9월 10일 오전 10:45(ET)에 발표합니다. 두 발표 모두 파이어사이드 채팅 형식으로 진행되며 웹캐스트로 시청할 수 있습니다.
CorMedix (NASDAQ:CRMD), une société biopharmaceutique spécialisée dans des produits thérapeutiques pour des affections potentiellement mortelles, a annoncé sa participation à deux grandes conférences pour investisseurs en santé en septembre 2025.
La direction présentera au Cantor Global Healthcare Conference le 5 septembre à 8h35 ET et au Morgan Stanley 23rd Annual Global Healthcare Conference le 10 septembre à 10h45 ET. Les deux interventions se dérouleront au format « fireside chat » et seront disponibles en webcast.
CorMedix (NASDAQ:CRMD), ein biopharmazeutisches Unternehmen, das therapeutische Produkte für lebensbedrohliche Erkrankungen entwickelt, kündigte seine Teilnahme an zwei wichtigen Gesundheitsinvestorenkonferenzen im September 2025 an.
Die Geschäftsführung wird am Cantor Global Healthcare Conference am 5. September um 8:35 Uhr ET und am Morgan Stanley 23rd Annual Global Healthcare Conference am 10. September um 10:45 Uhr ET präsentieren. Beide Präsentationen finden im Gesprächsformat "Fireside Chat" statt und werden per Webcast übertragen.
- None.
- None.
BERKELEY HEIGHTS, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in September.
Cantor Global Healthcare Conference
| Date: | September 5, 2025 |
| Time: | 8:35am Eastern |
| Format: | Fireside Chat |
| Webcast: | Link to webcast |
Morgan Stanley 23rd Annual Global Healthcare Conference
| Date: | September 10, 2025 |
| Time: | 10:45am Eastern |
| Format: | Fireside Chat |
| Webcast: | Link to webcast |
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath® in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix commenced clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath® as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
When is CorMedix (CRMD) presenting at the Cantor Global Healthcare Conference 2025?
What time is CorMedix's presentation at the Morgan Stanley Healthcare Conference 2025?
How can investors access CorMedix's (CRMD) conference presentations in September 2025?
Which investor conferences is CorMedix (CRMD) attending in September 2025?
